(NASDAQ: TVRD) Tvardi Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
Tvardi Therapeutics's earnings in 2025 is -$45,077,000.On average, 2 Wall Street analysts forecast TVRD's earnings for 2025 to be -$21,670,493, with the lowest TVRD earnings forecast at -$28,176,321, and the highest TVRD earnings forecast at -$15,164,664. On average, 2 Wall Street analysts forecast TVRD's earnings for 2026 to be -$29,954,893, with the lowest TVRD earnings forecast at -$36,694,744, and the highest TVRD earnings forecast at -$23,215,042.
In 2027, TVRD is forecast to generate -$58,599,259 in earnings, with the lowest earnings forecast at -$58,599,259 and the highest earnings forecast at -$58,599,259.